January 25, 2021
Business News

Ashvattha Therapeutics Announces Formation of Scientific Advisory Board


REDWOOD CITY, Calif.–()–Ashvattha Therapeutics, a clinical-stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeted to reactive inflammatory cells, to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced the formation of a Scientific Advisory Board (SAB), chaired by Kannan Rangaramanujam, Ph.D, founder and Chief Technology Officer. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.

“The scientific guidance of this group of experts will be invaluable as we translate HDTs to the clinic to help patients,” said Jeffrey Cleland,…



Click here to view the original article.

Related Posts

You might also like ...

NATO Selects Thales to Supply Its First Defence Cloud for the Armed Forces
Market Outlook for the Virtual Schools Market in North America to 2024, Featuring Abbotsford Virtual School, Acklam Grange School, Basehor-Linwood Virtual School, Charter Schools USA and More – ResearchAndMarkets.com
Riassunto: La NATO sceglie Thales per la fornitura della prima soluzione cloud per la difesa delle forze armate